Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120020/S034

Supera Peripheral Stent System

Abbott Vascular (Idef Technologies Inc) · Decision date Dec 9, 2025

FDA DECISIONP120020/S034

What did the FDA approve?

FDA records P120020/S034 as a supplement to PMA P120020, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 9, 2025.

FDA approval order statement

approval for a manufacturing site located at Synergy Health AST, SRL, B13.1 Street 4, Avenue 1, Coyol Free Zone, Coyol, Alajuela, 20102, Costa Rica for sterilization.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Dec 9, 2025
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P120020/S034
Regulatory pathway
PMA supplement
Product code
NIP
Decision code
APPR
Decision date
Dec 9, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Product code
NIP
FDA device class
3

For the original device and its historical approval scope, see PMA P120020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P120020 · Original PMA

    SUPERA PERIPHERAL STENT SYSTEM

  2. P120020/S034 received

    Application receipt date recorded by FDA.

  3. P120020/S034 · FDA decision

    Normal 180 Day Track No User Fee

  4. P120020/S035 · Related supplement

    Supera Peripheral Stent System

  5. P120020/S036 · Related supplement

    Supera Peripheral Stent System

  6. P120020/S037 · Related supplement

    Supera Peripheral Stent System

Timeline entries are records held by MedtechLedger for P120020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120020

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Vascular (Idef Technologies Inc)PMA approvalMar 28, 2014FDA
Abbott Vascular (Idef Technologies Inc)PMA supplementFeb 5, 2026FDA
Abbott Vascular (Idef Technologies Inc)PMA supplementMar 20, 2026FDA
Abbott Vascular (Idef Technologies Inc)PMA supplementNov 6, 2026FDA

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular (Idef Technologies Inc)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records